| 摘要 |
A selective ET A receptor antagonist for use in a method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy is disclosed, in particular wherein the selective ET A receptor antagonist comprises at least one agent selected from the group consisting of atrasentan, ambrisentan, avosentan, BMS 193884, BQ-123, CI-1020, clazosentan, darusentan, edonentan, S-0139, sitaxsentan, TA-0201, TBC 3711, YM-598, ZD-1611, ZD-4054, and salts thereof. Further, such selective ET A receptor antagonist is disclosed in combination with one or more antihypertensives other than selective ET A receptor antagonists for use in said method. Still further, such selective ET A receptor antagonist is disclosed in combination with one or more antidiabetics other than selective ET A receptor antagonists for use in said method. |
